Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. 

The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. 

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Refer to:

Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media)


Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

 

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-third-quarter-2025-financial-results-announcement-302585549.html

SOURCE Eli Lilly and Company

News Provided by PR Newswire via QuoteMedia

LLY
The Conversation (0)
Lilly announces departure of Anat Ashkenazi, chief financial officer

Lilly announces departure of Anat Ashkenazi, chief financial officer

Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I would like to thank Anat for her 23 years of... Keep Reading...
Melissa Seymour to join Lilly as executive vice president of Global Quality

Melissa Seymour to join Lilly as executive vice president of Global Quality

Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024 . Seymour currently serves as the chief quality officer for Bristol Myers Squibb and... Keep Reading...
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development Eli Lilly and Company... Keep Reading...
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases

Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases

New $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work... Keep Reading...
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA will participate in a fireside chat at 4 p.m. Eastern... Keep Reading...

Latest Press Releases

Related News